Clinicopathological Features and Molecular Typing of Invasive Fibroma of Abdominal Wall

NCT06204198 | Unknown

• 1 other identifier: SWYX:NO.2023-601
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Aggressive fibromatosis, also known as desmoid fibromatosis or desmoid tumor, is a fibrous tumor that occurs in the fascia, aponeurosis, or deep soft tissue and is formed by excessive proliferation of fibroblasts and myofibroblasts. At present, the disease is considered to be a borderline tumor. Due to the unclear boundary of the tumor, it often grows into the surrounding adjacent tissues, which is difficult to remove completely and easy to relapse. It has been reported that nuclear β-catenin expression and CTNNB1 gene mutation can be used for the differential diagnosis of aggressive fibromatosis from other spindle cell lesions. At present, there is a lack of multicenter retrospective clinical study of this disease, and there is no literature report on the postoperative quality of life of this kind of patients. This study intends to further explore the clinicopathological features, prognosis and molecular typing of abdominal wall aggressive fibroma by retrospective analysis of the case data of multiple hospitals, as well as sequencing analysis of the retained specimens and paraffin specimens from previous operations, to study the high risk factors for recurrence of the disease, and to further comprehensively analyze the impact of abdominal wall aggressive fibroma surgery on the quality of life of patients through follow-up.

Conditions

Aggressive Fibromatosis of Abdominal Wall (Disorder)

Outcome Measures

Primary Outcomes (3)

• Clinicopathological features checklist

  Clinicopathological features

  From September 2023 to September 2024

• Postoperative survival of patients

  Prognosis

  From September 2023 to September 2024

• Scores of patients' quality of life after surgery

  Patients' quality of life after surgery

  From September 2023 to September 2024

Interventions

No intervention OTHER

No intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who underwent resection at our hospital for aggressive fibroma in the abdominal wall.

You may qualify if:

• ① Surgical treatment for "invasive fibroma of abdominal wall"; ② Complete clinical data; ③ Agree to participate in the project.

You may not qualify if:

• ① can not cooperate with the project implementation; ② There is cognitive dysfunction; Refuse to participate in research projects.

Sponsors & Collaborators

• Shandong Provincial Hospital: lead

Study Sites (1)

Shandong Provincial Hospital

Jinan, Shandong, 250000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Surgical retained or paraffin specimens were obtained from patients.

Study Officials

• Yulong Shi, MD

  Shandong Provincial Hospital

  STUDY CHAIR

Central Study Contacts

Qiong Teng

CONTACT

18755138389; tengqiong2021@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident physician

Study Record Dates

• First Submitted: January 3, 2024
• First Posted: January 12, 2024
• Study Start: September 1, 2023
• Primary Completion: February 1, 2024
• Study Completion: September 1, 2024
• Last Updated: January 12, 2024

Record last verified: 2024-01

Locations

CN (1)